Larimar Therapeutics

Larimar Therapeutics

LRMR· Manufacturing· Fiscal year ends in December

CEO pay in FY2024Stock -14.9% in FY2024

Carole S. Ben-Maimon, M.D. is the CEO of Larimar Therapeutics and was paid $2.5M in FY2024 (Dec), down 20%.

Pay$100 in the stock at the end of FY21 → $36
CEO pay is from each Larimar Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives3

See all
  1. 1Carole S. Ben-Maimon, M.D.FY2024
  2. 2Michael CelanoFY2024
  3. 3Gopi Shankar, Ph.D., MBA, FAAPSFY2024

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Larimar Therapeutics paid its 3 named executives $5.1M in total in FY2024 (Dec). CEO Carole S. Ben-Maimon, M.D. was paid $2.5M of that.

Name
Carole S. Ben-Maimon, M.D.President and Chief Executive Officer
Michael CelanoChief Financial Officer and Secretary
Gopi Shankar, Ph.D., MBA, FAAPSChief Development Officer

of each named executive, from the Summary Compensation Table of each proxy.

Peers

No disclosed peer group

No proxy on file names a pay peer group for Larimar Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.

Activity

Filings6

See all
Proxy statementDEF 14AApr 20, 2026FY2025
Annual report10-KMar 19, 2026FY2025
Proxy statementDEF 14AApr 11, 2025FY2024
Annual report10-KMar 24, 2025FY2024
Proxy statementDEF 14AApr 29, 2024FY2023
Annual report10-KMar 14, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data